MP-A Seminars

The NHS 2050 net zero target requires a fundamental rethink in most pharmaceutical manufacturing processes. While the benefits of single use systems are significant in sterile processing, the sourcing, manufacturing, distribution, use and disposal of the products ultimately results in an environmental impact. Taking a lifecycle view when re-designing our products is key to achieve net zero targets.

Calum will discuss the application of full life cycle assessments in reducing environmental impact while retaining the desired performance.

The importance of eco-friendly excipients in promoting sustainability within the pharmaceutical industry cannot be overstated. Traditional excipients, while effective, often come with significant environmental footprints due to their synthetic origins, the chemicals used in their production, and the energy-intensive manufacturing processes involved. These conventional practices can contribute to pollution, resource depletion, and other ecological issues.

July 2022, NHS the first health care system which has introduced the net zero into legislation. Which means by 2045 to reduce the zero carbon footprint on all medicines. In this presentation we will look at regular excipients vs sustainable excipients and how you can reduce your carbon footprint.

We are at the dawn of a new era for laboratories and those working in them. The value output of labs is at the edge of being transformed by the opportunities presented by data systems, automation, smart technology, AI and machine learning.

The impacts of the growth of these technologies will be felt in all aspects of lab operations including people, skills, locations and buildings.

I will discuss:

- Change, adaptation and flexibility in the laboratory estate
- Smart data systems
- The business case for automation
- The vital role of design to foster collaboration across the labs landscape.

We’ll explore the transformative journey of implementing the My Green Lab program at AstraZeneca, a globally recognized certification that fosters sustainability within laboratory environments. The My Green Lab initiative not only engages employees in sustainable practices but also drives the development of innovative projects that contribute to cost savings and the efficient use of natural resources. By highlighting successful case studies and quantifiable outcomes, we will demonstrate how My Green Lab empowers our workforce to become active participants in environmental stewardship. Join us to learn how this program is reshaping our commitment to sustainability and generating tangible benefits for both our company and the planet.

This presentation will summarise AstraZeneca’s sustainability strategy, it’s Life Cycle Assessment programme for commercial products, and how we are integrating LCA principles into development projects through new innovative tools.

Having created a culture of sustainability across our lab spaces, we are looking towards the future of sustainability and what that means to the pharmaceutical industry. We will look at how the cultural shift has empowered the workforce to identify opportunities and drive innovative change through the organisation, leveraging automation, digitalisation and new ways of working to improve our efficiencies and our sustainable ways of working

In response to the amplified need for sustainable pharmaceutical supply chains and consumption patterns highlighted by events such as the COVID-19 pandemic, the ETERNAL project focuses on ensuring ongoing access to safe, high-quality, and effective pharmaceutical treatments while minimizing the environmental impact. The project embraces a full life cycle approach, encompassing design, manufacturing, usage, and disposal phases, and evaluates the environmental risks associated with active pharmaceutical ingredients, residues, metabolites, and other production-related by-products. Particular emphasis will be placed on advances in new solvent-free and continuous processing techniques in the preparation of medicines, thus adapting to the production requirements of the market and the increasingly high standards of sustainability.

The EU Fit for 55 focuses on specific topics that need particular attention and a strong green transition to achieve climate neutrality.

Within the ETERNAL project we have a focus on the application of Energy Efficiency Directive to the Pharmaceutical sector

Article 3 of the revised EED directive (EU/2023/1791), published in September 2023, provides a stronger and wider legal basis for the application of the principle “Energy Efficiency First”

Article 3 sets an obligation for EU countries to ensure that energy efficiency solutions are considered in planning, policy and investment decisions in both the energy and non-energy sectors.

Article 3 requires EU countries to develop and ensure the application of cost-benefit assessment methodologies that include proper assessment of the wider benefits of energy efficiency solutions from the societal perspective

The ETERNAL project will present how existing methodologies can be applied to show cost-benefits and develop new methodologies to assist asset owners in the pharmaceutical sector achieve higher energy performance for the energy services that are needed for production

A focus on energy services approach can provide a production driven design for sustainability, with energy performance criteria for equipment selection

HVAC in pharmaceutical production and/or distribution facilities represents the largest single element of facility CO2 footprint and one of the largest energy costs. Addressing it is a key step to decarbonisation and cost savings. On-Site Energy will explain energy and decarbonisation trends, as well as share case studies of the application of innovative technologies and integration with renewable energy. David will then explore the pros and cons of delivering solutions on a standard Capex basis vs a third-party's off-balance sheet PPA model.

The presentation is showing the significance of ESG regulations in today’s supply chain landscape, main requirements, critical points to control and responsibility that can be transferred to downstream/suppliers. The practical advice is to be shared on how to move from discussions on sustainability to clear actions within procurement department: Tier 1&2 suppliers assessing for carbon footprint contribution, auditing, cooperation on Science Based Targets achievement. Particular examples will be introduced on the sustainability platform (Ecovadis) and sustainable packaging solutions in pharmaceutical industry.

In a scientific data driven sector we must transition our understanding and communication around sustainability from qualitative to quantitative. Quantifiable metrics and shared tools enable better communication and collaboration, which is vital considering most emissions lie in supply chains. To address this, we need good (not perfect) data available to access.

We’ll give an overview of some key sustainability metrics and tools that enable targeted strategy and actions, while making it possible to capture and communicate progress more meaningfully. Covering ‘Carbon’, PCFs, and LCAs, including what they are, their value, limitations, and key challenges with examples, including LCA case studies.

As sustainability becomes an increasingly critical priority, our latest innovations focus on providing eco-friendlier alternatives to traditional WFI production methods. This presentation will explore how electrical WFI stills and pure steam generators can significantly reduce environmental impact by utilising electrical energy rather than relying on conventional fossil fuels. We will discuss the reduced carbon footprint, increased energy efficiency, and the operational cost savings these systems offer, highlighting the potential for pharmaceutical manufacturers to not only meet regulatory standards but also to align with global sustainability goals.

Managing industrial assets in pharmaceutical manufacturing is crucial for ensuring efficiency, compliance, and safety.  Engineers consider all elements from accurately registering assets, having the right preventative and predictive maintenance regimes based on risk management and building competency in staff.  Data driven decision making is critical to help identify opportunities for continuous improvement.